Global Information
회사소개 | 문의 | 비교리스트

여성 성기능 장애 : 파이프라인 리뷰

Female Sexual Dysfunction (Women´s and Male Health) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 192588
페이지 정보 영문 90 Pages 배송안내
가격
US $ 2,000 ₩ 2,548,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,096,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,645,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


여성 성기능 장애 : 파이프라인 리뷰 Female Sexual Dysfunction (Women´s and Male Health) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 90 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

여성 성기능 장애는 일반 성행위에서 다양한 신체적 단계의 일부 또는 전부를 건전하게 경험할 수 없는 경우에 발생합니다. 소인으로 우울증과 불안신경증, 심혈관 질환, 간 또는 신장 장애, 특정 약물(항울제, 고혈압약 등) 등이 있습니다. 에스트로겐 치료 등이 이루어집니다.

여성 성기능 장애(Female Sexual Dysfunction) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

여성 성기능 장애 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

개발중인 치료제 : 기업별

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

개발중인 제품 : 기업별

치료제 개발에 참여하고 있는 기업

  • Apricus Biosciences, Inc.
  • Emotional Brain BV
  • EndoCeutics, Inc.
  • M et P Pharma AG
  • Palatin Technologies, Inc.
  • Re-Pharm Limited
  • TherapeuticsMD, Inc.
  • Valeant Pharmaceuticals International, Inc.

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

파이프라인 제품의 최신 동향

휴지 상태 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

도표

KSM 16.09.20

List of Tables

List of Tables

  • Number of Products under Development for Female Sexual Dysfunction, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Female Sexual Dysfunction - Pipeline by Applied Biology Inc, 2021
  • Female Sexual Dysfunction - Pipeline by Autotelic Bio Inc, 2021
  • Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, 2021
  • Female Sexual Dysfunction - Pipeline by Can-Fite BioPharma Ltd, 2021
  • Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, 2021
  • Female Sexual Dysfunction - Pipeline by Emotional Brain BV, 2021
  • Female Sexual Dysfunction - Pipeline by Endoceutics Inc, 2021
  • Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, 2021
  • Female Sexual Dysfunction - Pipeline by Ivix Ltd, 2021
  • Female Sexual Dysfunction - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2021
  • Female Sexual Dysfunction - Pipeline by Lennham Pharmaceuticals Inc, 2021
  • Female Sexual Dysfunction - Pipeline by M et P Pharma AG, 2021
  • Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, 2021
  • Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd (Inactive), 2021
  • Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, 2021
  • Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, 2021
  • Female Sexual Dysfunction - Pipeline by Thomas Advanced Medical LLC, 2021
  • Female Sexual Dysfunction - Dormant Projects, 2021
  • Female Sexual Dysfunction - Dormant Projects, 2021 (Contd..1)
  • Female Sexual Dysfunction - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Female Sexual Dysfunction, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Drugs In Development, 2021, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 2, 8, 1, 1, 6, 3 and 1 respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Female Sexual Dysfunction - Overview
  • Female Sexual Dysfunction - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Female Sexual Dysfunction - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Female Sexual Dysfunction - Companies Involved in Therapeutics Development
  • Female Sexual Dysfunction - Drug Profiles
  • Female Sexual Dysfunction - Dormant Projects
  • Female Sexual Dysfunction - Discontinued Products
  • Female Sexual Dysfunction - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q